短链脂肪酸调节肠脑轴在耐药性癫痫小鼠模型中发挥疾病修饰作用
该研究在匹罗卡品诱导的耐药性癫痫小鼠模型中,补充乙酸、丙酸和丁酸的平衡混合物可减少癫痫进展表型比例、使进展指数降低3倍,并改善癫痫簇集和认知缺陷,同时恢复海马与肠道病理改变、部分正常化脑内短链脂肪酸水平。
要点
- 短链脂肪酸补充未显著改变总体每日癫痫发作频率,但使进展指数降低3倍。
- 治疗减少癫痫簇集、改善认知缺陷并恢复海马和肠道病理改变。
- 癫痫小鼠代谢组学与人类癫痫脑组织分析支持肠脑轴功能障碍参与疾病进展。
核心结论
- 补充短链脂肪酸能够改变实验性耐药性癫痫的疾病轨迹,具有明确的转化意义。
研究设计与样本
- 成年雄性小鼠经状态癫痫持续后,接受乙酸、丙酸和丁酸平衡混合物或溶媒治疗。
- 通过脑电图监测癫痫频率和时序进展70天,终点评估认知、脑与肠道组织病理及神经炎症。
- 对粪便和血液进行代谢组学分析,并分析小鼠及耐药性癫痫患者脑组织的短链脂肪酸水平和受体表达。
主要发现
- 短链脂肪酸补充减少呈现进展表型的小鼠比例,并使总体进展指数降低3倍。
- 治疗未显著改变总体每日癫痫发作频率,但减少了癫痫簇集。
- 治疗改善了认知缺陷,恢复了海马和肠道改变,并部分正常化脑内短链脂肪酸水平。
- 癫痫小鼠代谢组学与人类癫痫脑组织分析支持肠脑轴功能障碍对疾病进展的机制性贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Drug-resistant epilepsy (DRE) remains a clinical challenge, as therapies modifying disease trajectory are lacking. Increasing evidence implicates gut microbiota dysbiosis in epilepsy pathophysiology, with short-chain fatty acids (SCFAs) emerging as key microbial metabolites with neuroprotective and anti-inflammatory properties. Clinical studies show that people with DRE exhibit gut microbiota alterations that may impair fecal SCFAs production. Here, we investigated whether supplementation of SCFAs confers disease-modifying effects in a preclinical model of DRE. METHODS: Adult male mice were subjected to status epilepticus (SE) and subsequently treated with a balanced mixture of acetate, propionate, and butyrate, or vehicle. Seizure frequency and temporal progression were monitored for 70 days by electroencephalography (EEG). At the study end point, cognitive performance, brain and gut histopathology, and neuroinflammation were assessed, together with metabolomic profiling of feces and blood. Brain SCFA levels and receptor expression were also analyzed in mice and in brain tissue from individuals with DRE. RESULTS: SCFA supplementation reduced the proportion of mice exhibiting a progressive phenotype and decreased the overall progression index (PI) 3-fold, without significantly altering overall daily seizure frequency. Treatment reduced seizure clustering, improved cognitive deficits, restored hippocampal and intestinal alterations, and partially normalized cerebral SCFAs levels. Metabolomic profiling in epileptic mice and analysis of human epilepsy brain tissue support a mechanistic contribution of gut-brain axis dysfunction to disease progression. INTERPRETATION: These findings identify SCFAs supplementation as a therapeutic strategy capable of modifying disease trajectory in experimental DRE, with clear translational relevance. ANN NEUROL 2026;100:613-627.
引用
- Bera AA, Sapia RD, Volpedo G, et al. Gut-Brain Axis Modulation by Short-Chain Fatty Acids Exerts Disease-Modifying Effects in a Murine Model of Drug-Resistant Epilepsy. Ann Neurol. 2026. PMID: 42322241. doi:10.1002/ana.78283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。